CONTEXT: Fenofibrate is a peroxisome proliferator-activated receptor (PPAR)-α agonist that showed beneficial effects on total cardiovascular risk in patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. OBJECTIVE: This study aimed to investigate the long-term effect of fenofibrate therapy on three novel biomarkers of cardiovascular risk, namely adipocyte-fatty acid-binding protein (A-FABP), fibroblast growth factor 21 (FGF21), and retinol-binding protein 4 (RBP4), which are all downstream targets of PPAR-α or PPAR-γ, in patients with type 2 diabetes. DESIGN, SETTING, AND PATIENTS: A total of 216 patients (108 in the fenofibrate group and 108 in the placebo group) were randomly selected from the FIELD study cohort. A-FABP, FGF21, and RBP4 levels were measured in serum samples at both baseline and the fifth year of the study. RESULTS: Relative to the placebo group, the changes of serum FGF21 and RBP4 levels were 85% (P < 0.001) and 10% (P = 0.032) higher in the fenofibrate group, respectively, over 5 yr. Fenofibrate treatment had no detectable effect on serum A-FABP level (P > 0.05). The effect of fenofibrate treatment on serum FGF21, but not RBP4, remained significant after adjusting for fenofibrate-induced changes in glycosylated hemoglobin, total cholesterol, triglycerides, apolipoprotein A-II, fibrinogen, plasma creatinine, and homocysteine (P = 0.002). CONCLUSIONS: Long-term fenofibrate treatment could increase serum FGF21 levels over 5 yr in patients with type 2 diabetes. Additional studies are needed to investigate the potential role of FGF21 in the fenofibrate-mediated reduction of cardiovascular risk.
RCT Entities:
CONTEXT: Fenofibrate is a peroxisome proliferator-activated receptor (PPAR)-α agonist that showed beneficial effects on total cardiovascular risk in patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. OBJECTIVE: This study aimed to investigate the long-term effect of fenofibrate therapy on three novel biomarkers of cardiovascular risk, namely adipocyte-fatty acid-binding protein (A-FABP), fibroblast growth factor 21 (FGF21), and retinol-binding protein 4 (RBP4), which are all downstream targets of PPAR-α or PPAR-γ, in patients with type 2 diabetes. DESIGN, SETTING, AND PATIENTS: A total of 216 patients (108 in the fenofibrate group and 108 in the placebo group) were randomly selected from the FIELD study cohort. A-FABP, FGF21, and RBP4 levels were measured in serum samples at both baseline and the fifth year of the study. RESULTS: Relative to the placebo group, the changes of serum FGF21 and RBP4 levels were 85% (P < 0.001) and 10% (P = 0.032) higher in the fenofibrate group, respectively, over 5 yr. Fenofibrate treatment had no detectable effect on serum A-FABP level (P > 0.05). The effect of fenofibrate treatment on serum FGF21, but not RBP4, remained significant after adjusting for fenofibrate-induced changes in glycosylated hemoglobin, total cholesterol, triglycerides, apolipoprotein A-II, fibrinogen, plasma creatinine, and homocysteine (P = 0.002). CONCLUSIONS: Long-term fenofibrate treatment could increase serum FGF21 levels over 5 yr in patients with type 2 diabetes. Additional studies are needed to investigate the potential role of FGF21 in the fenofibrate-mediated reduction of cardiovascular risk.
Authors: Paulo Giovanni de Albuquerque Suassuna; Rogério Baumgratz de Paula; Hélady Sanders-Pinheiro; Orson W Moe; Ming-Chang Hu Journal: J Nephrol Date: 2018-11-14 Impact factor: 3.902
Authors: Kwok-Leung Ong; Robyn L McClelland; Matthew A Allison; John Kokkinos; Ben J Wu; Philip J Barter; Kerry-Anne Rye Journal: Atherosclerosis Date: 2018-10-17 Impact factor: 5.162
Authors: Chi Ho Lee; Chloe Y Y Cheung; Yu Cho Woo; David T W Lui; Michele M A Yuen; Carol H Y Fong; Wing Sun Chow; Amin Xu; Karen S L Lam Journal: Diabetologia Date: 2018-09-28 Impact factor: 10.122
Authors: Asma Ejaz; Laura Martinez-Guino; Allison B Goldfine; Francesc Ribas-Aulinas; Valeria De Nigris; Sílvia Ribó; Alba Gonzalez-Franquesa; Pablo M Garcia-Roves; Elizabeth Li; Jonathan M Dreyfuss; Walt Gall; Jason K Kim; Teodoro Bottiglieri; Francesc Villarroya; Robert E Gerszten; Mary-Elizabeth Patti; Carles Lerin Journal: Diabetes Date: 2016-02-08 Impact factor: 9.461
Authors: Kwok-Leung Ong; Andrzej S Januszewski; Rachel O'Connell; Luke Buizen; Alicia J Jenkins; Aimin Xu; David R Sullivan; Philip J Barter; Russell S Scott; Marja-Riitta Taskinen; Kerry-Anne Rye; Anthony C Keech Journal: Diabetologia Date: 2015-06-09 Impact factor: 10.122
Authors: Kwok-Leung Ong; Andrzej S Januszewski; Rachel O'Connell; Alicia J Jenkins; Aimin Xu; David R Sullivan; Philip J Barter; Wei-Ting Hung; Russell S Scott; Marja-Riitta Taskinen; Anthony C Keech; Kerry-Anne Rye Journal: Diabetologia Date: 2014-11-26 Impact factor: 10.122
Authors: Tsz Him Hui; Robyn L McClelland; Matthew A Allison; Carlos J Rodriguez; Richard A Kronmal; Susan R Heckbert; Erin D Michos; Philip J Barter; Kerry-Anne Rye; Kwok Leung Ong Journal: Atherosclerosis Date: 2017-12-25 Impact factor: 5.162